Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves vs. prostate cancer: new MRI-Guided treatment shows promise

NCT ID NCT03996005

Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to treat early-stage prostate cancer using MRI-guided ultrasound waves to destroy tumors without surgery. 25 men with low-to-intermediate risk prostate cancer received the treatment. The main goal was to see if no significant cancer remained one year later, based on follow-up biopsies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Sep 2019

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

80 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patient ≥ 50 years old * Histologically confirmed adenocarcinoma of the prostate * Gleason ≤ 7 (3 + 4) ; Grade group ≤ 2 according to Epstein * Clinically \<T3, N0, M0 * PSA \< 15 ng/mL * Prostate volume \<100g * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Life expectancy higher than 12 months in the judgement of the investigator * Radiological TNM (prostate MRI) T ≤ 2 (absence of extra-capsular extension, absence of seminal vesicle invasion), N = 0, M = 0 * First line of treatment or relapse after initial radiotherapy * Willing to give signed, informed consent freely * Able to adhere to the follow-up schedule and other protocol requirements. Exclusion Criteria: * Contraindication to MRI * Contraindication to general anesthesia * Presence or history of any other malignancy except for non-melanoma skin cancer adequately treated at least 2 years before study entry * Unreversible haemostasis disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ablation therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ablation therapy Localized prostate cancer Mri guided transurethral ultrasound ablation

Contacts and locations

Locations

  • Hôpitaux Universitaires de strasbourg

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.